MAPK10 and early-onset autosomal dominant Alzheimer disease: Based on knockout experiments and its specific tissue expression, JNK3 has emerged as a promising target for potential treatments of neuroinflammation and neurodegenerative disorders like Huntington’s disease [2,3,4], Parkinson’s disease [5], and Alzheimer’s disease [6,7,8,9,10,11,12,13].